Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 5/20 | 0.53 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGAV | P06756 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2234718 | 1.00 | MME (0.53) | MMETGFBR1SMN1; SMN2ALDH1A1ITGB3 | |
| SCHEMBL18190834 | 0.85 | ALDH1A1 (0.58) | MMESMN1; SMN2ALDH1A1FOLH1MEN1 | |
| SCHEMBL12514588 | 0.85 | PLG (0.48) | MMETGFBR1SMN1; SMN2PLGPLAU | |
| SCHEMBL2236885 | 0.84 | SMN1; SMN2 (0.49) | MMESMN1; SMN2ALDH1A1ITGB3ITGAV | |
| SCHEMBL8088657 | 0.84 | SMN1; SMN2 (0.49) | MMESMN1; SMN2ALDH1A1ITGB3ITGAV | |
| SCHEMBL2236878 | 0.84 | SMN1; SMN2 (0.49) | MMESMN1; SMN2ALDH1A1ITGB3ITGAV | |
| SCHEMBL6763914 | 0.84 | SMN1; SMN2 (0.53) | MMESMN1; SMN2ALDH1A1ITGB3ITGAV | |
| SCHEMBL4756588 | 0.83 | TGFBR1 (0.45) | MMETGFBR1SMN1; SMN2FOLH1 | |
| Hydrochloric Acid SCHEMBL7652855 | 0.82 | SMN1; SMN2 (0.47) | MMESMN1; SMN2ALDH1A1ITGB3ITGAV | |
| SCHEMBL17224588 | 0.81 | TGFBR1 (0.53) | MMETGFBR1SMN1; SMN2ITGB3ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130041180-A1 | PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2013-02-14 | — | — | US | claimed |
| EP-2534127-A1 | PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE | MSN Laboratories Limited (IN) | 2012-12-19 | — | — | EP | claimed |
| WO-2011099033-A1 | PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE | MSN LABORATORIES LIMITED (IN) | 2011-08-18 | — | — | WO | claimed |
| US-8907132-B2 | Process for preparing (R)-2-acetamido-N-benzyl-3-methoxy-propionamide | MSN LABORATORIES PRIVATE LIMITED (IN) | 2014-12-09 | — | — | US | disclosed |
| US-20130041180-A1 | PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2013-02-14 | — | — | US | disclosed |
| EP-2534127-A1 | PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE | MSN Laboratories Limited (IN) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011099033-A1 | PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE | MSN LABORATORIES LIMITED (IN) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130041180-A1 | PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE | AMY1A, PTMA, NAAA | MME 306/4885TGFBR1 2124/4885SMN1; SMN2 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.